Cogent Biosciences Highlights Additional Data with Six Bezuclastinib Posters from SUMMIT Trial at 2026 AAAAI Annual Meeting
Cogent Biosciences, Inc. (COGT)
Last cogent biosciences, inc. earnings: 11/8 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.cogint.com/investor-relations
Company Research
Source: GlobeNewswire
Bezuclastinib mean TSS reduction deepens to –32.0 points at 48 weeks of treatment with further improvement shown across all measured symptoms99% of patients achieve 50% reduction in serum tryptase at 48 weeks, with 83% rate of normalizationStrong evidence of bezuclastinib’s potential as first disease modifying agent for NonAdvSM patient population given clear correlation between objective measures of disease burden and symptomatic improvement WALTHAM, Mass. and BOULDER, Colo., Feb. 28, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced additional clinical results from the pivotal SUMMIT trial with bezuclastinib in patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) at the American Academy of Allergy Asthma & Immunology (AAAAI) Annual Meeting. As previously reported, bezuclastinib demonstrated clinically meaningful and highly statistically s
Show less
Read more
Impact Snapshot
Event Time:
COGT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
COGT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
COGT alerts
High impacting Cogent Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
COGT
News
- A Look At Cogent Biosciences (COGT) Valuation After Recent Share Price Volatility [Yahoo! Finance]Yahoo! Finance
- Bezuclastinib SUMMIT Data Reframe Cogent Biosciences Mastocytosis Opportunity [Yahoo! Finance]Yahoo! Finance
- Cogent Biosciences Inc. (COGT) Set for Bezuclastinib Launch, Awaiting FDA Approval [Yahoo! Finance]Yahoo! Finance
- Cogent Biosciences Highlights Additional Data with Six Bezuclastinib Posters from SUMMIT Trial at 2026 AAAAI Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Analyst Bullish on Cogent (COGT) Amid Expected Drug Approval [Yahoo! Finance]Yahoo! Finance
COGT
Sec Filings
- 2/17/26 - Form SCHEDULE
- 2/17/26 - Form S-8
- 2/17/26 - Form SCHEDULE
- COGT's page on the SEC website